SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 10.57% to Rs. 14145.20 millions for the quarter ended March 2024 as compared to Rs. 12793.40 millions during the corresponding quarter last year.A humble growth in net profit of 18.62% reported in the quarter ended March 2024 to Rs. 1213.20  millions from Rs. 1022.80 millions.The company reported a good operating profit of 2952.00 millions compared to 2583.80 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 14145.20 12793.40 10.57 48123.90 57734.50 -16.65 48123.90 57734.50 -16.65
Other Income 240.90 59.40 305.56 474.20 159.50 197.30 474.20 159.50 197.30
PBIDT 2952.00 2583.80 14.25 7973.00 14977.10 -46.77 7973.00 14977.10 -46.77
Interest 419.90 410.30 2.34 1508.20 1457.00 3.51 1508.20 1457.00 3.51
PBDT 2532.10 2173.50 16.50 6464.80 13520.10 -52.18 6464.80 13520.10 -52.18
Depreciation 889.00 805.50 10.37 3450.10 3005.80 14.78 3450.10 3005.80 14.78
PBT 1643.10 1368.00 20.11 3014.70 10514.30 -71.33 3014.70 10514.30 -71.33
TAX 429.90 345.20 24.54 777.70 2910.50 -73.28 777.70 2910.50 -73.28
Deferred Tax -29.50 270.80 -110.89 -101.70 202.70 -150.17 -101.70 202.70 -150.17
PAT 1213.20 1022.80 18.62 2237.00 7603.80 -70.58 2237.00 7603.80 -70.58
Equity 1077.90 1077.30 0.06 1077.90 1077.30 0.06 1077.90 1077.30 0.06
PBIDTM(%) 20.87 20.20 3.33 16.57 25.94 -36.13 16.57 25.94 -36.13

Laurus Labs Share Price

1114.00 -0.50 (-0.04%)
22-Apr-2026 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1662.75
Dr. Reddys Lab 1211.30
Cipla 1224.65
Zydus Lifesciences 925.75
Lupin 2290.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×